依瓦布拉定
医学
心力衰竭
心脏病学
内科学
冠状动脉疾病
心绞痛
心率
疾病
心肌梗塞
血压
作者
Michael Böhm,Jan‐Christian Reil,Prakash Deedwania,Jae Bum Kim,Jeffrey S. Borer
标识
DOI:10.1016/j.amjmed.2014.09.016
摘要
Resting heart rate is central to cardiac output and is influenced by changes occurring in numerous diseases. It predicts longevity and cardiovascular diseases, and current evidence suggests that it is also an important marker of outcome in cardiovascular disease, including heart failure. Beta-blockers improve outcomes in heart failure; however, they have effects outside reducing heart rate. Ivabradine has demonstrated efficacy in reducing rehospitalizations and mortality in heart failure and in improving exercise tolerance and reducing angina attacks in patients with coronary artery disease, whereas selective heart rate reduction may also prove to be beneficial in therapeutic areas outside those in which ivabradine has already demonstrated clinical efficacy. This review provides an update on the associations between heart rate and cardiovascular outcomes in various conditions, the experimental effects of heart rate reduction with ivabradine, and the potential new indications in cardiovascular disease.
科研通智能强力驱动
Strongly Powered by AbleSci AI